[Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].

Nov 11, 2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Progress on tirzepatide, a drug acting on appetite and blood sugar hormones, for treating obesity-related sleep apnea

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Tirzepatide significantly reduced the apnea hypopnea index (AHI) in patients with obstructive sleep apnea (OSA).

Obstructive sleep apnea is closely linked to obesity, which may worsen metabolic health.
Tirzepatide, a dual receptor agonist, shows potential benefits beyond weight loss in managing obesity.
In addition to reducing AHI, tirzepatide improved oxygen levels, blood pressure, and cardiovascular disease risk factors.
The mechanisms of tirzepatide's effects may include changes in fat distribution and inflammation.
These findings suggest potential advantages of tirzepatide for obese patients suffering from OSA.

AI simplified

Obstructive sleep apnea (OSA) is a common sleep-disordered breathing. Obesity is one of the primary risk factors for OSA, while OSA itself may promote weight gain by impairing metabolism and increasing insulin resistance, thereby creating a vicious cycle. Together, these conditions pose a persistent public health challenge. In recent years, tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist, has demonstrated therapeutic potential beyond weight loss in the management of obesity, encompassing various mechanisms. The recent SURMOUNT-OSA study showed that tirzepatide significantly reduced the apnea hypopnea index (AHI) in OSA patients and improved oxygen desaturation, blood pressure, and cardiovascular disease (CVD)-related risk factors. These effects are thought to be mediated not only by weight reduction, but also by modulation of fat distribution, inflammatory status, and autonomic nervous system function. This highlights the potential advantages of tirzepatide in obese patients with OSA. This review summarizes recent advances in tirzepatide research in this population, exploring its mechanisms of action, efficacy, and safety, with the aim of providing a theoretical basis for precision treatment strategies for OSA.

[Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief